Course Content
Module 1: Basic ECMO
Module I: Extracorporeal Membrane Oxygenation Basics (ECMO Basics) This module covers the foundational knowledge of ECMO, including circuit physiology, components, and basic ECMO management. Duration: 3 Weeks (Course weeks 1 to 3) Week 1: Introduction to ECMO Week 2: ECMO Physiology & Circuit Management Week 3: ECMO Complications and Troubleshooting Module I Pretest: 30 MCQs
0/20
Module II: Veno-venous Extracorporeal Membrane Oxygenation (VV ECMO)
This module focuses on the use of VV ECMO in patients with respiratory failure. Topics include ARDS management, VV ECMO cannulation strategies, and VV ECMO troubleshooting. Duration: 3 Weeks (Course weeks 4 to 6) Module II Pretest: 30 MCQs Week 4: VV ECMO Fundamentals Start Date: July 20, 2025 a. Respiratory failure and ARDS management (Ahmed Magdey) b. Evidence for VV ECMO use and landmark trials (Hesham Faisal) c. VV ECMO cannulation techniques and pros and cons of different VV ECMO configuration choices (Moustafa Esam) d. ECMO Retrieval and Patient Transport on ECMO (Ahmed Labib)
0/22
Module III: Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)
This module focuses on VA ECMO for cardiogenic shock, including cannulation strategies, LV unloading, and advanced applications. Duration: 3 Weeks (Course weeks 7 to 9) Module II Pretest: 30 MCQs
0/19
Extra Corporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS) course (Copy 4)

Anticoagulation During ECMO: Challenges and Protocols

1. Rationale for Anticoagulation

  • Prevent thrombosis in patient and ECMO circuit.

  • Balance between clotting risks (systemic emboli, oxygenator clot) and bleeding risks.

2. Anticoagulation Protocols

  • Heparin is standard: bolus at cannulation, then continuous infusion.

  • Targets vary by center:

    • ACT (80–180 sec), aPTT, anti-Xa.

    • Platelets maintained >50–60.

  • Other monitoring: daily clotting profile, fibrinogen, D-dimer.

3. Monitoring Methods

  1. ACT: rapid bedside, but altered by hypothermia/hemodilution.

  2. aPTT: widely used, but influenced by sepsis, liver disease.

  3. Anti-Xa: measures heparin activity, may reveal AT-III deficiency.

4. High Bleeding Risk Patients

  • Reduce anticoagulation targets or withhold completely.

  • Maintain high ECMO flow to reduce stasis/clot risk.

  • Vigilant circuit inspection, D-dimer, platelets, hemoglobin.

  • MDT discussion essential for daily decisions.

5. VV vs VA ECMO

  • VV ECMO: lower systemic clot risk, more flexible anticoagulation.

  • VA ECMO: bypasses lungs, higher risk of systemic emboli → stricter targets.

6. Complications

  • Bleeding: common at cannula sites, GI tract, or intracranial (neurosurgical options limited).

  • Thrombosis: circuit clot, systemic emboli, valve thrombus.

  • Circuit change may be required in clotting/hemolysis.

7. Heparin-Induced Thrombocytopenia (HIT)

  • Suspect with >50% platelet drop, new thrombosis.

  • Confirm with antibody and functional assays.

  • Stop all heparin (including flushes, coated lines).

  • Switch to Argatroban or Bivalirudin; monitor with aPTT.

8. Key Takeaways

  • Anticoagulation in ECMO is a dynamic balance.

  • Bleeding complications are more common, but thrombotic events are often catastrophic.

  • Protocol-driven, MDT-based management is essential to safely support patients.

Saving Lives Academy
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.